Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what his planned timeline is for the establishment of the naloxone supply network coordinators.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

Naloxone is a lifesaving medicine that reverses the effects of an opioid overdose, including highly potent synthetic opioids which are growing in prevalence in the United Kingdom. It is more important than ever to increase access to naloxone products, which will save lives.

Last year, the Department amended the Human Medicines Regulations 2012 to further expand access to naloxone. The legislation enabled more services and professionals to supply this medication, making it easier to access for people at risk, and for their loved ones.

Route 1 of the legislation increased the number of services and professionals specified in regulations who can provide take home naloxone. However, not all services and professions had an agreed statutory definition across the four nations of the UK. As such, route 2 of the legislation set up the legal framework, which includes supply network coordinators, for the creation of a registration service for services and professions who fall outside the definitions listed in route 1 to apply and to be able to provide take home naloxone. These legislative changes were the first step in expanding access to naloxone, which has resulted in naloxone being more readily available to supply in the community. Since these changes came into effect, the Government has worked with the devolved administrations and front-line services to explore the set-up and delivery of this registration service. We have encountered operational difficulties in establishing supply network co-ordinators in England which has delayed implementation. However, we have identified further legislative amendments to increase access to take-home and emergency use naloxone and, as such, we intend to launch a public consultation by the end of this year.

The Department has also published guidance, Supplying take home naloxone without a prescription, that sets out essential practical information such as who can supply naloxone, the products available, how to use naloxone and other basic lifesaving tools, and the training required. This guidance is available at the following link:

https://www.gov.uk/guidance/supplying-take-home-naloxone-without-a-prescription

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he expects the drug Vorsidenib (Voranigo) to be made available to treat adults and children aged 12 years and over with grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations on whether new medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over.

NICE published its draft guidance for consultation on 15 October and was unable to recommend it as a clinically and cost-effective use of NHS resources. The appraisal is still ongoing, and NICE will take the comments received fully into account in developing its final recommendations. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expect to publish final guidance in January 2026.

Question to the Department for Business and Trade:

To ask the Secretary of State for Business and Trade, what discussions he has had with Evri and other delivery companies on leaving parcels unattended on doorsteps.

Answered by Blair McDougall - Parliamentary Under Secretary of State (Department for Business and Trade)

It is unacceptable for delivery companies to leave parcels unattended on doorsteps where that has not been requested by a customer.

The government wants to see all operators provide a good level of service, including incorporating customers’ preferences on deliveries. However, Evri and other delivery companies are independent businesses, and the government has no role in their operational decisions.

Ofcom is the independent regulator for the postal sector with the responsibility and powers to regulate postal services.

Ofcom engages regularly with all parcel operators to understand their approach to implementation of, and compliance with, its consumer protection measures.

Independent Office for Police Conduct findings on Norman Bettison

Thanking postal workers